Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First phase III trial of APX 3330

Next Previous
Trial Profile

First phase III trial of APX 3330

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APX 3330 (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Inflammatory bowel diseases; Pancreatic cancer; Peripheral nervous system diseases; Retinal vein occlusion; Solid tumours
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 12 Nov 2024 According to an Opus Genetics media release, companys discussions remain ongoing with the FDA regarding the SPA for a Phase 3 program in DR.
  • 24 Jun 2020 New trial record
  • 17 Jun 2020 According to a Rexahn Pharmaceuticals media release, the company expect to initiate this trial in the second half of 2020 and topline results are expected as early as the first quarter of 2021 and throughout the remainder of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top